A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : ML / mucosal leishmaniasis

[Related PubMed/MEDLINE]
Total Number of Papers: 93
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   ML  (>> Co-occurring Abbreviation)
Long Form:   mucosal leishmaniasis
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2019 A biomarker for tegumentary and visceral leishmaniasis based on a recombinant Leishmania hypothetical protein. VL
2019 A randomized, open-label clinical trial comparing the long-term effects of miltefosine and meglumine antimoniate for mucosal leishmaniasis. CI
2019 Comparative study on liposomal amphotericin B and other therapies in the treatment of mucosal leishmaniasis: A 15-year retrospective cohort study. ABLC, AEs, CI, d-AMB, L-AmB, OR
2019 Cost-effectiveness analysis of Mucosal Leishmaniasis diagnosis with PCR-based vs parasitological tests in Colombia. DALY, DES, GDPpc, ICERs, IFA, MST, WTP
2019 Gene expression profile of cytokines produced in biopsies from patients with American cutaneous leishmaniasis. ACL, CL, FFPE, RQ
2019 In Situ Cellular Response Underlying Successful Treatment of Mucosal Leishmaniasis with a Combination of Pentavalent Antimonial and Pentoxifylline. PTX
2019 Mucosal Leishmaniasis in Travelers with Leishmania braziliensis Complex Returning to Israel. CL
2019 Phonotherapeutic Intervention in Patients With Mucosal Leishmaniasis Sequelae. CL
2019 Successful treatment by adding thalidomide to meglumine antimoniate in a case of refractory anthroponotic mucocutaneous leishmaniasis. ---
10  2018 Case Report: Mucosal Leishmaniasis Presenting with Nasal Septum Perforation after Almost Thirty Years. ---
11  2018 Cellular Markers of Active Disease and Cure in Different Forms of Leishmania infantum-Induced Disease. CL, LLL, PBMC, SLA, SLA-CPA, VL
12  2018 Diagnostic application of recombinant Leishmania proteins and evaluation of their in vitro immunogenicity after stimulation of immune cells collected from tegumentary leishmaniasis patients and healthy individuals. ---
13  2018 Mucosal leishmaniasis: the experience of a Brazilian referral center. AmB
14  2018 Promastigote parasites cultured from the lesions of patients with mucosal leishmaniasis are more resistant to oxidative stress than promastigotes from a cutaneous lesion. LCL, NO, ROS, TSA
15  2018 Safety and efficacy of miltefosine monotherapy and pentoxifylline associated with pentavalent antimony in treating mucosal leishmaniasis. ---
16  2017 AIM2 inflammasome is associated with disease severity in tegumentary leishmaniasis caused by Leishmania (V.) braziliensis. CL, TL
17  2017 Annexin A1 Is Involved in the Resolution of Inflammatory Responses during Leishmania braziliensis Infection. ANXA1, LCL, WT
18  2017 Dynamics of American tegumentary leishmaniasis in a highly endemic region for Leishmania (Viannia) braziliensis infection in northeast Brazil. ATL, CL, DL
19  2017 Field Validation of SYBR Green- and TaqMan-Based Real-Time PCR Using Biopsy and Swab Samples To Diagnose American Tegumentary Leishmaniasis in an Area Where Leishmania (Viannia) braziliensis Is Endemic. ATL, CI, CL
20  2017 Mucosal leishmaniasis: A Retrospective Study of 327 Cases from an Endemic Area of Leishmania (Viannia) braziliensis. ATL
21  2016 Intestinal helminth coinfection is associated with mucosal lesions and poor response to therapy in American tegumentary leishmaniasis. ATL, PSE
22  2016 Leishmania (Viannia) braziliensis amastigotes from patients with mucosal leishmaniasis have increased ability to disseminate and are controlled by nitric oxide at the early stage of murine infection. iNOS, LCL
23  2016 Otolaryngological manifestations of leishmaniosis. CL, NTD, VL
24  2016 Quantitative Kinetoplast DNA Assessment During Treatment of Mucosal Leishmaniasis as a Potential Biomarker of Outcome: A Pilot Study. kDNA-qPCR, PL
25  2015 Correlation between presence of Leishmania RNA virus 1 and clinical characteristics of nasal mucosal leishmaniosis. LRV1, PCR
26  2015 Efficacy and Safety of Liposomal Amphotericin B for the Treatment of Mucosal Leishmaniasis from the New World: A Retrospective Study. ---
27  2015 Further Evidence of an Association between the Presence of Leishmania RNA Virus 1 and the Mucosal Manifestations in Tegumentary Leishmaniasis Patients. CL, DCL, DL, TL
28  2015 Mucosal leishmaniasis of the lip: an emerging clinical form in Tunisia. MA, PCR
29  2015 Mucosal leishmaniasis with primary oral involvement: a case series and a review of the literature. ---
30  2015 Wound healing genes and susceptibility to cutaneous leishmaniasis in Brazil: role of COL1A1. Col1a1, FBAT, Mmp1, SNPs
31  2014 Antigen-triggered interferon-gamma and interleukin-10 pattern in cured mucosal leishmaniasis patients is shaped during the active phase of disease. Con A, ELISPOT, IFN, IL, Lb-Ag, MST, PBMC, Tg-Ag
32  2014 Facial structure alterations and abnormalities of the paranasal sinuses on multidetector computed tomography scans of patients with treated mucosal leishmaniasis. MDCT
33  2014 LeishMan recommendations for treatment of cutaneous and mucosal leishmaniasis in travelers, 2014. CL
34  2014 Liposomal formulation of amphotericin B for the treatment of mucosal leishmaniasis in HIV-negative patients. LAB
35  2014 Reactivation of mucosal and cutaneous leishmaniasis in a renal transplanted patient. ---
36  2014 The role of inflammatory and anti-inflammatory cytokines in the pathogenesis of human tegumentary leishmaniasis. CL
37  2014 Voice disorders in mucosal leishmaniasis. ---
38  2013 Candidate gene case-control and functional study shows macrophage inhibitory factor (MIF) polymorphism is associated with cutaneous leishmaniasis. ATL, CL, MIF, SNPs
39  2013 Cutaneous leishmaniasis in Switzerland: first experience with species-specific treatment. CL
40  2013 Immunologic response and memory T cells in subjects cured of tegumentary leishmaniasis. CL, LST, SLA
41  2013 Influence of the nutritional status in the clinical and therapeutical evolution in adults and elderly with American Tegumentary Leishmaniasis. ATL, BMI
42  2013 Molecular, cytological, and immunocytochemical study and kDNA sequencing of laryngeal Leishmania infantum infection. ---
43  2013 Mucosal leishmaniasis: an underestimated presentation of a neglected disease. ---
44  2013 Real-time PCR assay for detection and quantification of Leishmania (Viannia) organisms in skin and mucosal lesions: exploratory study of parasite load and clinical parameters. CL, G6PD, kDNA, qPCR
45  2012 A proposed new clinical staging system for patients with mucosal leishmaniasis. ---
46  2012 Association between an emerging disseminated form of leishmaniasis and Leishmania (Viannia) braziliensis strain polymorphisms. ATL, CL, DL, SNPs
47  2012 Comparative study of the in situ immune response in oral and nasal mucosal leishmaniasis. NOS2
48  2012 Cutaneous leishmaniasis in Royal Marines from Oruzgan, Afghanistan. CL, VL
49  2012 Genetic polymorphism in Leishmania (Viannia) braziliensis detected in mucosal leishmaniasis of HIV-infected and non-HIV-infected patients. LSSP-PCR, PCR
50  2012 Improvements in obtaining New World Leishmania sp from mucosal lesions: notes on isolating and stocking parasites. CL
51  2012 Local or systemic treatment for New World cutaneous leishmaniasis? Re-evaluating the evidence for the risk of mucosal leishmaniasis. CL
52  2012 Macrophages participate in host protection and the disease pathology associated with Leishmania braziliensis infection. CL, HS, NO, SC
53  2012 Mixed mucosal leishmaniasis infection caused by Leishmania tropica and Leishmania major. ---
54  2012 Molecular diagnosis and species identification of mucosal leishmaniasis in Iran and correlation with cytological findings. ---
55  2012 Transcriptome patterns from primary cutaneous Leishmania braziliensis infections associate with eventual development of mucosal disease in humans. LCL
56  2011 American tegumentary leishmaniasis and HIV-AIDS association in a tertiary care center in the Brazilian Amazon. AIDS, ATL, HIV
57  2011 Clinical, histopathologic, and cytologic diagnosis of mucosal leishmaniasis and literature review. ---
58  2011 First report on Ambisome-associated allergic reaction in two Sudanese leishmaniasis patients. PKDL
59  2011 FLI1 polymorphism affects susceptibility to cutaneous leishmaniasis in Brazil. CL, OR
60  2011 MMP-9 activity is induced by Leishmania braziliensis infection and correlates with mucosal leishmaniasis. LCL, MMP-9
61  2011 Mucosal Leishmaniasis caused by Leishmania (Viannia) braziliensis and Leishmania (Viannia) guyanensis in the Brazilian Amazon. PCR
62  2011 Non-invasive cytology brush PCR diagnostic testing in mucosal leishmaniasis: superior performance to conventional biopsy with histopathology. LST
63  2010 A clinical trial to evaluate the safety and immunogenicity of the LEISH-F1+MPL-SE vaccine when used in combination with sodium stibogluconate for the treatment of mucosal leishmaniasis. ---
64  2010 Human mucosal leishmaniasis: neutrophils infiltrate areas of tissue damage that express high levels of Th17-related cytokines. CCR6
65  2010 Mucosal leishmaniasis and abnormalities on computed tomographic scans of paranasal sinuses. CT
66  2010 The -2518bp promoter polymorphism at CCL2/MCP1 influences susceptibility to mucosal but not localized cutaneous leishmaniasis in Brazil. CL, FBAT, MCP-1, NC
67  2009 Mucosal leishmaniasis in a Sudanese patient. VL
68  2008 Histopathology of mast cells and cytokines during healing of human mucosal leishmaniasis. MCs
69  2008 Local immunological factors associated with recurrence of mucosal leishmaniasis. ---
70  2008 Mucosal leishmaniasis . Current scenario and prospects for treatment. ---
71  2007 Can interferon-gamma and interleukin-10 balance be associated with severity of human Leishmania (Viannia) braziliensis infection? ASY, CCL, CL, CML, ELISA, IFN, IL, PBMC, SH
72  2007 Differential immune regulation of activated T cells between cutaneous and mucosal leishmaniasis as a model for pathogenesis. PBMC
73  2007 Treatment of mucosal leishmaniasis in Latin America: systematic review. ---
74  2006 Concomitant early mucosal and cutaneous leishmaniasis in Brazil. ---
75  2006 Generic sodium stibogluconate is as safe and effective as branded meglumine antimoniate, for the treatment of tegumentary leishmaniasis in Isiboro Secure Park, Bolivia. CL, SSG
76  2006 IL6 -174 G/C promoter polymorphism influences susceptibility to mucosal but not localized cutaneous leishmaniasis in Brazil. CI, CL, FBAT, IL, OR, Th
77  2006 Immunotherapy for drug-refractory mucosal leishmaniasis. CC
78  2006 Mucosal leishmaniasis patients display an activated inflammatory T-cell phenotype associated with a nonbalanced monocyte population. CL, SLA
79  2005 Decreased in situ expression of interleukin-10 receptor is correlated with the exacerbated inflammatory and cytotoxic responses observed in mucosal leishmaniasis. CL, IL-10
80  2005 Effect of LACK and KMP11 on IFN-gamma production by peripheral blood mononuclear cells from cutaneous and mucosal leishmaniasis patients. CL, IFN-gamma, IL-10, KMP11, LACK, PBMC, SLA
81  2005 Familial aggregation of mucosal leishmaniasis in northeast Brazil. CL, DTH
82  2005 Polymerase chain reaction (PCR) is highly sensitive for diagnosis of mucosal leishmaniasis. MST, PCR
83  2004 New world mucosal and cutaneous leishmaniasis: an emerging health problem among British travellers. CL
84  2003 Mucosal leishmaniasis: in situ characterization of the host inflammatory response, before and after treatment. ---
85  2003 Short report: persistence of tumor necrosis factor-alpha in situ after lesion healing in mucosal leishmaniasis. TNF-alpha
86  2003 [On the origin and spread of cutaneous and mucosal leishmaniasis, based on pre- and post- colombian historical source]. ---
87  2002 Parasitological and immunological follow-up of American tegumentary leishmaniasis patients. CL, DNA, IFN-gamma, PCR
88  2002 T-cell-mediated immune responses in patients with cutaneous or mucosal leishmaniasis: long-term evaluation after therapy. CL, IL-5
89  2000 Mucosal leishmaniasis: quantitative nasal cytology as a marker of disease activity and indicator of healing. CL, QNCs
90  1998 An evaluation of clinical, serologic, anatomopathologic and immunohistochemical findings for fifteen patients with mucosal leishmaniasis before and after treatment. IISR
91  1997 Parasite-driven in vitro human lymphocyte cytotoxicity against autologous infected macrophages from mucosal leishmaniasis. CL
92  1991 Studies on the leishmaniases in the Sudan. 3. Clinical and parasitological studies on visceral and mucosal leishmaniasis. VL
93  1985 Cell mediated immunity in American cutaneous and mucosal leishmaniasis. CL